Platinum Cancer Treatment Gets Go Ahead
Platinum Cancer Treatment Gets Go Ahead
A new platinum based treatment for ovarian and small cell lung cancer has been approved for clinical trials by Chinese authorities. Poniard Pharmaceuticals was granted Clinical Trial Application approval to progress with two Phase III clinical studies of picoplatin.
Picoplatin is said to have already shown results in the treatment of cancer according to Poniard Pharmaceuticals. It is designed to overcome platinum resistance associated with chemotherapy in solid tumours, the company explained.
Chief Executive Ronald A Martell has said the decision is a "milestone" that will allow extra leverage for the company as it works towards completing it's strategic review.
"We believe that CTA approval from the SFDA enhances picoplatin's value proposition to potential partners in two important disease settings in which picoplatin has demonstrated strong clinical potential," he added.
